Combined treatment of Insulin Degludec intermediates

Insulin Degludec intermediates can be combined with other oral hypoglycemic drugs and pancreatic insulin. When pre-mixed insulin therapy is not effective, basic insulin therapy can also be used. So what is the combined treatment of Insulin Degludec intermediates? Next, let us take a look.

Here is that the content:

l Insulin Degludec intermediates combined with metformin

l Insulin Degludec intermediates combined with an a-glycosidase inhibitor

l Insulin Degludec intermediates combined with sulfonylureas or Glinides

l Insulin Degludec intermediates combined with dipeptidyl peptidase

l Insulin Degludec intermediates combined with thiazolidinediones

l Insulin Degludec intermediates combined with glucose transport protein inhibitor

l Insulin Degludec intermediates combined with glucagon-like peptide receptor agonist

l Insulin Degludec intermediates combined meal insulin therapy

Insulin Degludec intermediates combined with metformin

Combined with Insulin Degludec intermediates can further reduce postprandial blood glucose, improve insulin resistance, inhibit glycogen output, and increase the uptake and utilization of glucose by peripheral tissues. It is complementary to the mechanism of Insulin Degludec intermediates and has a low risk of hypoglycemia and no weight gain. Obviously, but still, need to pay attention to the risk of hypoglycemia and the adverse gastrointestinal reactions of metformin.

Insulin Degludec intermediates combined with an a-glycosidase inhibitor

A-glycosidase inhibitors can inhibit glycosidase activity and delay the absorption of sugars in the small intestine. Combining Insulin Degludec intermediates can further reduce postprandial blood glucose, but it is necessary to pay attention to the risk of hypoglycemia and the poor digestive reaction of a-glycosidase inhibitors.

Insulin Degludec intermediates combined with sulfonylureas or Glinides

Such drugs can stimulate the secretion of insulin in 3 cells of the islet, increase the level of insulin in the body, and further reduce the benefits of day-to-day blood sugar, but the risk of hypoglycemia should be paid attention to.

Insulin Degludec intermediates combined with dipeptidyl peptidase

It can increase the level of endogenous glucagon-like peptide-1 (GLP-1), enhance the secretion of insulin, and inhibit the secretion of glucagon. Combining Insulin Degludec intermediates can further improve blood sugar, but attention should be paid to the risk of hypoglycemia.

Insulin Degludec intermediates combined with thiazolidinediones

Thiazolidinediones increase the sensitivity of peripheral tissues to the action of insulin and increase the utilization of glucose. Combined with Insulin Degludec intermediates can further improve blood sugar and reduce insulin consumption, but it may cause water and sodium retention and increase the risk of heart failure and fracture.

Insulin Degludec intermediates combined with glucose transport protein inhibitor

Glucose transporter 2 inhibitors can inhibit the reabsorption of glucose in the proximal renal tubules so that a large amount of glucose is excreted from the urine. Combined with Insulin Degludec intermediates, it has the benefits of further improving blood sugar, synergistically lowering blood sugar, low risk of hypoglycemia, and less weight gain. But there are risks of hypoglycemia, reproductive system infections, and ketoacidosis.

Insulin Degludec intermediates combined with glucagon-like peptide receptor agonist

Membrane glucagon-like peptide receptor stimulant can increase the level of glucagon-like peptide in the body, enhance the secretion of insulin, and inhibit the secretion of glucagon. Combining Insulin Degludec intermediates can further improve blood sugar, synergistically lower blood sugar, and reduce weight gain, but it is necessary to pay attention to the risk of hypoglycemia and the adverse reactions of the digestive tract of glucagon-like peptide receptor agonist.

Insulin Degludec intermediates combined meal insulin therapy

When the patients who are treated with Insulin Degludec intermediates combined with oral hypoglycemic drugs still have poor blood glucose control or in special periods, they can be treated with meal Insulin Degludec intermediates. In the treatment of basic insulin combined with meal insulin, attention should be paid to the applicable population, starting dose, and dosage adjustment plan.

Applicable people: Oral hypoglycemic drugs combined with basic insulin therapy, fasting blood glucose has reached the standard or the dose of Insulin Degludec intermediates is large. But the glycosylated hemoglobin is still not up to standard; patients with poor blood glucose control or large blood glucose fluctuations after repeated premixed insulin therapy; patients who need to correct hyperglycemia in a short time; hyperglycemia with obvious symptoms of hyperglycemia Diagnose type 2 diabetes.

Chengdu Pukang has a professional R&D team with first-class technology, rich experience, and innovative ideas, which can meet the various needs of customers from custom synthesis to mass production. Parking has sufficient resources to provide process development, optimization, and scale-up production. The R & D will cooperate with the production to solve the problems encountered in the pilot scale-up process. We are more professional, more efficient to provide customers with high-quality products.